Laurus Labs growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
+22.7%+10.2%−16.6%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
+68.5%+35.7%−51.2%
+107.6%+59.1%−69.0%
+148.4%+120.8%−79.5%
+147.7%+123.2%−79.7%
+12.6%+11.3%+9.5%
+18.0%+11.8%+1.7%
+169.8%−9.6%−33.0%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

LAURUSLABS₹2,244.00

Laurus Labs Ltd.

· Pharma & Health
₹ CrorePeersDIVISLABGLANDMANKINDBIOCONALKEMLUPINFORTISGLENMARKMcap ₹1.21L Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/09/2026
Revenue Growth—-16.6+10.2+22.7—
EBITDA Growth—-51.2+35.7+68.5—
EBIT Growth—-69.0+59.1+107.6—
Net Income Growth—-79.5+120.8+148.4—
EPS Growth—-79.7+123.2+147.7—
Total Assets Growth—+9.5+11.3+12.6—
Total Equity Growth—+1.7+11.8+18.0—
Cash from Operations Growth—-33.0-9.6+169.8—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.